IR BioSciences Holdings, Inc. Announces a 2-for-1 Forward Stock Split
06 April 2004 - 11:02PM
PR Newswire (US)
IR BioSciences Holdings, Inc. Announces a 2-for-1 Forward Stock
Split SCOTTSDALE, Ariz., April 6 /PRNewswire-FirstCall/ -- IR
Biosciences Holdings, Inc. (BULLETIN BOARD: IRBO) (formerly OTC
Bulletin Board: IRBH) today announcedthat its Board of Directors
approved a two-for-one forward stock split of its common stock.
Each share of the Company's common stock held by each stockholder
of record at the close of business on April 5, 2004 (record date)
will be reclassified and subdivided into two shares of the
Company's common stock. Each stockholder of record at the close of
business on the record date may turn in their stock certificates to
the transfer agent for new stock certificates. In connection with
the forward stock split, the Company's trading symbol changed from
"IRBH" to "IRBO" effective at the opening of the markets on April
6, 2004. The stock will continue to trade on the OTC Bulletin
Board. About IR BioSciences Holdings, Inc. IR BioSciences Holdings,
Inc.,formed in 2003, is the sole owner of ImmuneRegen BioSciences,
Inc., a biotechnology company engaged in the research and
development of applications utilizing modified Substance P, a
naturally occurring immunomodulator. Derived from homeostatic
substance P, ImmuneRegen has named their proprietary compound
"Homspera." IR BioSciences Holdings, Inc.'s initial focus is on the
continuing development of Homspera for various applications for use
in improving pulmonary function and stimulating the human immune
system. For more information, please visit the company's website at
http://www.immuneregen.com/. The matters discussed in this news
release contain forward looking statements including relating to
the plans of IR BioSciences Holdings, Inc. to effect a two-for-one
forward stock split and the timing thereof that are subject to
certain risks and uncertainties. IRBH assumes no obligation to
update the information in this release. DATASOURCE: IR BioSciences
Holdings, Inc. CONTACT: media, Michelle Derden of Spelling
Communications, +1-310-477-9500, ; or investors, Tony Schor of
InvestorAwareness, +1-847-945-2222, , both for IR BioSciences
Holdings, Inc. Web site: http://www.immuneregen.com/
Copyright